Page last updated: 2024-12-05

veratramine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

veratramine: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

veratramine : A piperidine alkaloid comprising the 14,15,16,17-tetradehydro derivative of veratraman having two hydroxy groups at the 3- and 23-positions. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6070
CHEMBL ID464724
CHEBI ID9951
SCHEMBL ID335680
MeSH IDM0054518

Synonyms (43)

Synonym
(3beta,23r)-14,15,16,17-tetradehydroveratraman-3,23-diol
(3beta,23beta)-14,15,16,17-tetradehydroveratraman-3,23-diol
CHEBI:9951 ,
V0148
nsc23880 ,
nsc-23880
wln: l d6 b566 lu&tttj a1 e1 oq fy1&- bt6mtj cq e1
veratraman-3, 14,15,16,17-tetradehydro-, (3.beta.,23.beta.)-
nsc-17821
(2s,3r,5s)-2-[(1s)-1-[(3s,6ar,11as,11br)-3-hydroxy-10,11b-dimethyl-1,2,3,4,6,6a,11,11a-octahydrobenzo[a]fluoren-9-yl]ethyl]-5-methyl-piperidin-3-ol
NSC17821 ,
veratramine
60-70-8
nsc 23880
nsc 17821
brn 0055515
hsdb 3545
veratraman-3,23-diol, 14,15,16,17-tetradehydro-, (3-beta,23-beta)-
veratraman-3,23-diol, 14,15,16,17-tetradehydro-, (3beta,23beta)-
CHEMBL464724
(2s,3r,5s)-2-[(1s)-1-[(3s,6ar,11as,11br)-3-hydroxy-10,11b-dimethyl-1,2,3,4,6,6a,11,11a-octahydrobenzo[a]fluoren-9-yl]ethyl]-5-methylpiperidin-3-ol
S3911
bdbm50396007
BCP0726000092
5-21-05-00297 (beilstein handbook reference)
unii-rk363yg315
rk363yg315 ,
3-piperidinol, 5-methyl-2-((1s)-1-((3s,6ar,11as,11br)-2,3,4,6,6a,11,11a,11b-octahydro-3-hydroxy-10,11b-dimethyl-1h-benzo(a)fluoren-9-yl)ethyl)-, (2s,3r,5s)-
veratramine [mi]
HY-N0837
SCHEMBL335680
AC-33967
(2s,3r,5s)-2-((s)-1-((3s,6ar,11as,11br)-3-hydroxy-10,11b-dimethyl-2,3,4,6,6a,11,11a,11b-octahydro-1h-benzo[a]fluoren-9-yl)ethyl)-5-methylpiperidin-3-ol
AKOS030526858
mfcd00468124
BS-17189
nsc17821;nsc23880
Q15427945
DTXSID40871534
CCG-268761
(3beta,23beta)-14,15,16,17-teradehydroveratraman-3,23-diol
A868905
nsc 23880; (2s,3r,5s)-5-methyl-2-[(1s)-1-[(3s,6ar,11as,11br)-2,3,4,6,6a,11,11a,11b-octahydro-3-hydroxy-10,11b-dimethyl-1h-benzo[a]fluoren-9-yl]ethyl]-3-piperidinol;

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" In order to elucidate the underling mechanism, in vivo pharmacokinetic experiments and in vitro mechanistic studies have been conducted."( Gender-Dependent Pharmacokinetics of Veratramine in Rats: In Vivo and In Vitro Evidence.
Kou, F; Lyu, C; Wei, H; Zhang, N; Zhang, S; Zhang, Y; Zhou, W; Zuo, Z, 2016
)
0.71
" The developed method was successfully applied to the pharmacokinetic and metabolic study of veratramine in mice after oral administration of veratramine."( Pharmacokinetics and metabolism study of veratramine in mice after oral administration using LC-MS/MS.
Cai, Z; Cong, Y; Li, SS; Shen, S; Wang, JY; Zhang, JL, 2016
)
0.92
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
piperidine alkaloid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
CholinesteraseHomo sapiens (human)IC50 (µMol)19.46000.00001.559910.0000AID697830
CholinesteraseEquus caballus (horse)IC50 (µMol)10.78000.00002.22149.4000AID697829
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (12)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processCholinesteraseHomo sapiens (human)
learningCholinesteraseHomo sapiens (human)
negative regulation of cell population proliferationCholinesteraseHomo sapiens (human)
neuroblast differentiationCholinesteraseHomo sapiens (human)
peptide hormone processingCholinesteraseHomo sapiens (human)
response to alkaloidCholinesteraseHomo sapiens (human)
cocaine metabolic processCholinesteraseHomo sapiens (human)
negative regulation of synaptic transmissionCholinesteraseHomo sapiens (human)
response to glucocorticoidCholinesteraseHomo sapiens (human)
response to folic acidCholinesteraseHomo sapiens (human)
choline metabolic processCholinesteraseHomo sapiens (human)
acetylcholine catabolic processCholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (9)

Processvia Protein(s)Taxonomy
amyloid-beta bindingCholinesteraseHomo sapiens (human)
catalytic activityCholinesteraseHomo sapiens (human)
acetylcholinesterase activityCholinesteraseHomo sapiens (human)
cholinesterase activityCholinesteraseHomo sapiens (human)
protein bindingCholinesteraseHomo sapiens (human)
hydrolase activity, acting on ester bondsCholinesteraseHomo sapiens (human)
enzyme bindingCholinesteraseHomo sapiens (human)
choline bindingCholinesteraseHomo sapiens (human)
identical protein bindingCholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
extracellular regionCholinesteraseHomo sapiens (human)
nuclear envelope lumenCholinesteraseHomo sapiens (human)
endoplasmic reticulum lumenCholinesteraseHomo sapiens (human)
blood microparticleCholinesteraseHomo sapiens (human)
plasma membraneCholinesteraseHomo sapiens (human)
extracellular spaceCholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID1224817Assays to identify small molecules inhibitory for eIF4E expression2015Chemistry & biology, Jul-23, Volume: 22, Issue:7
Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds.
AID399393Cytotoxicity against african green monkey Vero cells1998Journal of natural products, Jan, Volume: 61, Issue:1
Microbial biotransformation of veratramine.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID697829Inhibition of horse BChE by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID697831Inhibition of electric eel AChE by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID697830Inhibition of human BChE by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID509546Inhibition of hedgehog receptor mediated Gli transcription2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Modulators of the hedgehog signaling pathway.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (63)

TimeframeStudies, This Drug (%)All Drugs %
pre-199036 (57.14)18.7374
1990's9 (14.29)18.2507
2000's5 (7.94)29.6817
2010's10 (15.87)24.3611
2020's3 (4.76)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.18 (24.57)
Research Supply Index4.17 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (3.13%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other62 (96.88%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]